ClinicalTrials.gg
TerminatedNCT01464034Updated Aug 1, 2022

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1/2 interventional study of Carfilzomib and Pomalidomide in Multiple Myeloma, sponsored by Criterium, Inc.. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Criterium, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
21st of 113
136 · median 54
Started
2011
with 6 others
Phase 1/2
28 of 113
3 open now
Registered
19th of 113
by date

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 21st largest by enrollment, is one of 7 that started in 2011, is one of 28 in phase 1/2, and was the 19th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.

Read the detailed description

This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy. The study will explore the efficacy of CPD including overall response, time to progression, progression free survival, and time to next therapy.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cytopathologically or confirmed dx of multiple myeloma
  • to the most recently received therapy.
  • All pts must have received prior lenalidomide therapy and been determined to be refractory, relapsed, or intolerant.
  • , as indicated by one or more of the following:

Serum M-protein ≥ 0.5 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light Chain as per IMWG criteria, and abnormal ratio

  • Pts must be ≥ 18 years of age
  • of more than 3 months
  • PS of 0-2
  • Adequate hepatic function, with \< 2 times the (ULN), and (AST) and alanine aminotransferase (ALT) \< 3 times ULN
  • Uric acid must be within laboratory normal range
  • ≥ 50 mL/min
  • Additional Laboratory Requirements ≥1.0 x 109/L ≥8 g/dL(transfusion permitted) count ≥50.0 x 109/L
  • Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks
  • Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
  • Screening platelet count should be independent of platelet transfusions for at least 2 weeks.
  • Written in accordance with federal, local, and institutional guidelines
  • FCBP must agree to ongoing pregnancy testing
  • FCBP must have a negative serum or urine pregnancy test and agree to .
  • Male pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant. The patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant.
  • Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study.
  • All pts must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
  • Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin ( 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion

Exclusion criteria

Exclusion Criteria:

  • Pts with known sensitivity to any immunomodulatory drugs (IMiDs)
  • Use of any other experimental drug or therapy within 21 days prior to first dose
  • Exposure to any prior chemotherapy, use, or other myeloma treatment within 14 days prior to first dose. Pts currently on long term steroids do not require any . in addition, steroid use for spinal cord compression is permitted and does not require a washout period.
  • Radiation therapy within 14 days prior to first dose
  • Known allergies to carfilzomib or Captisol
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Current diagnosis of plasma cell leukemia
  • Waldenström's macroglobulinemia
  • Major surgery within 21 days prior to first dose
  • Pregnant or lactating females
  • Congestive heart failure ( class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months prior to first dose.
  • Uncontrolled hypertension
  • Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
  • Pts receiving active treatment or intervention for any other or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.
  • Serious psychiatric or medical conditions that could interfere with treatment
  • Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment
  • to any of the required concomitant drugs, including proton-pump inhibitor (e.g. lansoprazole), enteric-coated aspirin or if a history of prior thrombotic disease, warfarin or low molecular weight heparin
  • Pts in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment
  • Pts with primary systemic amyloidosis
  • Pts who have received prior treatment with carfilzomib (Phase II only)
  • Pts who have received prior treatment with pomalidomide (Phase II only)
  • Pts who have received prior treatment with both carfilzomib \& pomalidomide (Phase I only)
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Carfilzomib, Pomalidomide, Dexamethasone

    All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.

    Drug: Carfilzomib · Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days

    Also known as: PR-171

  • PO daily on Days 1-21, every 28 Days

    Also known as: CC-4047

  • 40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Adverse Events as a Measure of Safety and Tolerability

    Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment.

    Time frame: Throughout treatment, estimated at 2-12 months per patient

  2. Overall Response in Phase II

    Overall Response (SD, MR, PR, VGPR, CR, sCR)

    Time frame: Every 28 days while on treatment (estimated at 2- 12 months per patient)

Secondary outcomes

  1. Overall Response in Phase I

    Overall response (SD, MR, PR, VGPR, CR, sCR)

    Time frame: Every 28 days while on treatment (estimated at 2- 12 months per patient)

  2. Time to Progression

    Time frame: Every 28 days while on treatment (estimated at 2-12 months per patient)

  3. Progression Free Survival

    Time frame: throughout follow up (every 2-3 months for 2 years)

  4. Time to next therapy

    Time frame: throughout follow up (every 2-3 months for 2 years)

07

Study locations

9 sites
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • The John Theurer Cancer Center @ Hackensack UMC
    Hackensack, New Jersey 07601, United States
  • Columbia University
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Pennsylvania Abramson Cancer Center
    Philadelphia, Pennsylvania 19105, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
08

References and documents

Publications

  • Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17. PubMed 26384354 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jul 2020 and a completion of Jul 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2011
First posted
Nov 3, 2011
Start
Nov 2011
Primary completionActual
Jul 2020
CompletionActual
Jul 2020
Last update
Aug 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01464034
Lead sponsor
Criterium, Inc.
Responsible party
Sponsor
First posted
Nov 3, 2011
Start date
Nov 2011
Primary completion
Jul 2020
Completion
Jul 2020
Last update
Aug 1, 2022

Study contacts

Jatin Shah, MD
principal investigator · AMyC
Brian GM Durie, MD
principal investigator · AMyC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Pomalidomide

Start the discussion